This text is a result of machine translation.
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Beijing Pilots The DRG External Payment Mode
DRG refers to the diagnosis-related group used to classify the patient and set up a system to ensure the care provided is necessary. The National Healthcare Security Administration will pay the hospital a predetermined amount according to a patient’s DRG.
Jul 16, 2022 12:12 AM
CES 2026 in Numbers | From Shenzhen to Las Vegas: Huaqiangbei’s Year-End Report
Jan 15, 2026 09:42 PM
How Malaysia Became Southeast Asia’s “Computing Power Hub”
Jan 07, 2026 12:24 PM
Consumer-Grade 3D Printing Going Global Is Reaching a Watershed
Dec 29, 2025 05:40 PM